Open Access

Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis

  • Konstantinos N Fountoulakis1Email author,
  • Xenia Gonda2,
  • Eduard Vieta3 and
  • Frank Schmidt4
Annals of General Psychiatry20098:27

DOI: 10.1186/1744-859X-8-27

Received: 29 September 2009

Accepted: 31 December 2009

Published: 31 December 2009

Abstract

Background

We present a systematic review and meta-analysis of the available clinical trials concerning the usefulness of aripiprazole in the treatment of the psychotic symptoms in bipolar disorder.

Methods

A systematic MEDLINE and repository search concerning clinical trials for aripiprazole in bipolar disorder was conducted.

Results

The meta-analysis of four randomised controlled trials (RCTs) on acute mania suggests that the effect size of aripiprazole versus placebo was equal to 0.14 but a more reliable and accurate estimation is 0.18 for the total Positive and Negative Syndrome Scale (PANSS) score. The effect was higher for the PANSS-positive subscale (0.28), PANSS-hostility subscale (0.24) and PANSS-cognitive subscale (0.20), and lower for the PANSS-negative subscale (0.12). No data on the depressive phase of bipolar illness exist, while there are some data in favour of aripiprazole concerning the maintenance phase, where at week 26 all except the total PANSS score showed a significant superiority of aripiprazole over placebo (d = 0.28 for positive, d = 0.38 for the cognitive and d = 0.71 for the hostility subscales) and at week 100 the results were similar (d = 0.42, 0.63 and 0.48, respectively).

Conclusion

The data analysed for the current study support the usefulness of aripiprazole against psychotic symptoms during the acute manic and maintenance phases of bipolar illness.

Background

The treatment of bipolar disorder (BD) is difficult since the illness itself is complex [17]. In the BD clinical picture, psychotic features are a very frequent manifestation although they are not considered to constitute a core feature of the disorder. Delusions are relatively more common than hallucinations. However, it is reported that unipolar-depressed patients who later 'convert' to BD over time, as well as bipolar depressives, manifest more frequently psychotic features and pathological (psychotic) guilt [8, 9]. Additionally, within the BD patient group it has been suggested (but not proven) that those patients with a history of psychotic symptoms suffer from a greater impairment regarding the neuropsychological performance especially concerning verbal memory and executive function [10, 11].

Psychotic features include delusions and hallucinations and both can be mood congruent or non-congruent depending on their content. Mood congruent psychotic features include those entirely consistent with the thought content (either manic or depressive) while mood incongruent features are largely unrelated to thought content. Overexaggerated thoughts of guilt, sin, worthlessness, poverty and somatic health, or on the contrary thoughts of exceptional mental and physical fitness or special talents, wealth, some kind of grandiose identity or importance are mood congruent delusions, and even persecutory ideas or ideas of reference when in accord with the thought content can be considered to be mood congruent. Non-congruent delusions include nihilistic delusions (Cotard delusion or Cotard syndrome, negation delusion), bizarre delusions and sometimes the delusions can be so excessive that the identity itself changes. Psychotic symptoms have a profound effect on insight especially in depressive episodes which otherwise are characterised by a fair degree of insight. Psychotic features and the lack of insight might lead to the refusal of any treatment and to the need for an involuntary admission to a hospital.

Only during the last few years have antipsychotics and especially atypicals or second-generation antipsychotics (SGAs) gained a position in the treatment of BD [12, 13]. Their efficacy against acute mania is reported to be independent of sedation or of their effect on psychotic symptoms. Olanzapine, risperidone, quetiapine, ziprasidone and aripiprazole are approved for the treatment of acute mania, quetiapine and the olanzapine-fluoxetine combination are approved for the treatment of acute bipolar depression, and olanzapine, quetiapine and aripiprazole are approved for maintenance phase treatment.

Aripiprazole (7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), is a derivative of the dopamine autoreceptor agonist 7-(3-[4-(2,3-dimethylphenyl)piperazinyl]propoxy)-2(1H)-quinolinone (OPC-4392) [14, 15], was developed by Otsuka in Japan and was first approved by the US Food and Drug Administration (FDA) in 2002 for the treatment of schizophrenia.

Although psychotic symptoms are common in bipolar patients, not all randomised controlled trials (RCTs) include their assessment and up to now there has been no review or meta-analysis on the efficacy of agents approved for the treatment of BD on these specific symptoms. The aim of the current review and meta-analysis was to focus on outcome measures of randomised controlled trial testing the efficacy of aripiprazole against psychotic symptoms in bipolar disorder. To the best of our knowledge no such analysis exists in the literature to date, and the reviews available [1625] either do not include all the trials that have been conducted so far or do not focus on psychotic symptoms.

Methods

Search criteria

The first step of the search included a keyword search of Medline and the internet via Google with the words 'aripiprazole' and 'bipolar'.

The second step included search of the BMS site http://www.bms.com/clinical_trials/ as well as several relevant online repositories including http://clinicaltrials.gov, http://www.clinicalstudyresults.org and http://www.cochrane.org. The third step included scanning of the reference lists of various review and meta-analysis papers [2128].

Types of studies

The studies selected were RCTs with placebo or a comparator.

Data extraction

All data were extracted by the same author (KNF) from the full published paper or the clinical study report synopsis. In some cases some of the data were extracted or calculated from published meta-analysis or reviews.

Meta-analysis method

The following indices were calculated. Effect size (Cohen d) was calculated as the mean change divided by the standard deviation of the scale. It represents the difference between two groups in the amount of change.

Pooled standard deviation (SDp) was calculated by the following function:
https://static-content.springer.com/image/art%3A10.1186%2F1744-859X-8-27/MediaObjects/12991_2009_Article_1411_Equa_HTML.gif

Where Sp is the pooled standard deviation, ni is the sample size of the ith sample, si is the standard deviation of the ith sample, and k is the number of samples being combined.

The Q test for testing the homogeneity of studies was computed by summing the squared deviations of each study's effect estimate from the overall effect estimate, weighting the contribution of each study by its inverse variance. This was calculated only for the Young Mania Rating Scale (YMRS) and for placebo-controlled RCTs concerning the differential d versus placebo and for all studies concerning the absolute effect of aripiprazole. Not rejecting the homogeneity hypothesis leads to a fixed effects model because it is assumed that the estimated effect sizes only differ by sampling error, while the rejection of the homogeneity assumption leads to a random effects model that includes both intrastudy and interstudy variability.

The I2 index measures the extent of true heterogeneity, and was calculated by dividing the difference between the result of the Q test and its degrees of freedom (k-1) by the Q value itself and multiplying by 100. This index can be interpreted as the percentage of the total variability in a set of effect sizes due to true heterogeneity, that is, to interstudy variability.

The Hunter-Schmidt meta-analysis software was used for the correction of the effect sizes (d) for sampling error and measurement error [29] concerning only the effect size which calibrated the difference between two groups in the amount of change (aripiprazole vs placebo).

Acute mania/mixed episodes

Six trials assessed the efficacy of aripiprazole against acute manic/mixed episodes. Theses were CN138-009 [30], CN138-074 or NCT00036101 [31], CN138-135 or NCT00095511 [27], CN138-162 or NCT00097266 [32], CN138-007 which was negative and not published [33], CN138008 [34] and CN138-077 or NCT00046384, which did not produce any results due to the small number of patients recruited. Two of them (CN138-007 and CN138-077/NCT00046384) included a fixed dosage while the others included a flexible dosage design. Rapid cycling patients were excluded from CN138-135/NCT00095511. CN138-077/NCT00046384 did not produce any results due to the small number of patients recruited (29 in the aripiprazole arm and 27 in the placebo arm). Its design included also a fixed dosage, and it was prematurely closed because it was expected to produce negative results similar to CN138-007. All used YMRS as the primary outcome measure. Data on Positive and Negative Syndrome Scale (PANSS) is not reported by CN138009 and CN138007, while data for PANSS total only and some but not all subscales are reported by CN138074 and CN138135.

The details of these studies (randomised patients, efficacy and safety sample, publications and results) are shown in Table 1. The baseline scores for all outcome scales are shown in Table 2. The similarity of baseline scores across trials and the similar pooled mean justified the pooling of all data concerning each arm across studies irrespective whether the specific study had a placebo or a comparator arm or not. The dropout rates are shown in Table 3. The changes in the PANSS scales scores are shown in Table 4. The effect sizes (d) are shown in Table 5. The side effects frequency is shown in Table 6. The forest plot is shown in Figure 1.
Table 1

List of acute mania trials of aripiprazole and their characteristics

Trial

Publication

Duration

COMP

PLC

Randomised, N

Efficacy sample, N

Safety sample, N

Results

     

AR

COMP

PLC

AR

COMP

PLC

AR

COMP

PLC

 

CN138-009

Keck et al., 2003 [27]

3 weeks

No

Yes

        

127

Agent > PLC

CN138-074/NCT00036101

Sachs et al., 2006 [28]

3 weeks

No

Yes

137

 

135

136

 

132

136

 

133

Agent > PLC

CN138-135/NCT00095511

Keck et al., 2009 [29]

12 weeks

Li

Yes

155

160

165

154

155

163

154

159

164

Agent = comparator > PLC

CN138-162/NCT00097266

Young et al., 2009 [30]

12 weeks

Hal

Yes

167

165

153

152

161

152

166

165

153

Agent = comparator > PLC

CN138-007

Unpublished

3 weeks

No

Yes

267

 

134

267 -

 

134 -

267 -

 

134 -

Agent = PLC

CN138-077/NCT00046384

Unpublished

3 weeks

No

Yes

29

 

27

      

No results

CN138008

Vieta et al., 2005 [32]

12 weeks

Hal

No

175

172

 

171

158

 

175

169

 

Agent > comparator

All RCTs

Total by groups

    

1,060

497

746

1,005

474

704

1,025

493

711

 

Total

      

2,303

  

2,183

  

2,229

 

Only RCTs with PANSS data

              

Total by groups

    

663

497

480

613

474

447

631

493

450

 

Total

      

1,640

  

1,534

  

1,574

 

Dash indicates missing data. AR = aripiprazole; COMP = comparator; PANSS = Positive and Negative Syndrome Scale; PLC = placebo; RCT = randomised controlled trial.

Table 2

The baseline scale scores in aripiprazole randomised controlled trials (RCTs) of acute mania.

Trial

PANSS-total

PANSS-positive

PANSS-negative

PANSS-cognitive

PANSS-hostility

N (efficacy sample)

Aripiprazole

CN138-009

-

-

-

-

-

125

CN138-074

61.8 ± 16.7

-

-

-

-

136

CN138-135

62.0 ± 13.7

-

-

15.2 ± 3.4

10.1 ± 3.4

154

CN138-162

54.8 ± 10.3

16.0 ± 3.9

9.6 ± 2.6

14.7 ± 3.9

9.7 ± 2.6

152

CN138-007

-

-

-

-

-

267 -

CN138008

-

-

-

-

-

171

Pooled mean

59.5

16.0

9.6

14.9

9.9

1,005

Pooled SD

13.7

3.9

2.6

3.6

3.0

 

Placebo

CN138-009

-

-

-

-

-

123

CN138-074

62.5 ± 16.5

-

-

-

-

132

CN138-135

63.9 ± 13.1

-

-

15.3 ± 3.6

10.4 ± 3.6

163

CN138-162

54.4 ± 10.3

16.4 ± 4.9

9.4 ± 2.5

14.9 ± 3.7

9.7 ± 2.5

152

CN138-007

-

-

-

-

-

134 -

CN138008

      

Pooled mean

60.3

16.4

9.4

15.1

10.0

704

Pooled SD

13.4

4.9

2.5

3.6

3.1

 

Comparator

CN138-009

      

CN138-074

      

CN138-135

63.2 ± 12.9

-

-

15.6 ± 3.5

10.5 ± 3.5

155

CN138-162

54.1 ± 10.3

16.1 ± 3.9

9.5 ± 2.5

14.6 ± 3.9

9.4 ± 2.5

161

CN138-007

      

CN138008

-

-

-

-

-

158

Pooled mean

58.6

16.1

9.5

15.1

9.9

474

Pooled SD

11.6

3.9

2.5

3.7

3.0

 

Dash indicates missing data.

aCalculated from Suppes et al. 2008 [21]; data were not used for the calculation of the pooled mean because there is no data on the change.

PANSS = Positive and Negative Syndrome Scale.

Table 3

Dropout in aripiprazole randomised controlled trials (RCTs) for acute mania; data concern numbers of patients while the last row concerns rates

Trial

Aripiprazole

Placebo

Comparator

 

3 weeks

12 weeks

3 weeks

3 weeks

12 weeks

 

Total

LE

AE

CW

Total

LE

AE

CW

Total

LE

AE

CW

Total

LE

AE

CW

Total

LE

AE

CW

CN138-009

76

23

11

25

    

104

53

13

38

        

CN138-074

58

12

12

34

    

64

28

10

26

        

CN138-135

82

9

23

15

113

12

31

70

87

36

13

10

82

26

21

5

106

26

28

52

CN138-162

41

9

14

18

72

13

24

35

44

14

16

14

44

10

8

26

70

11

18

41

CN138-007

                    

CN138008

41

-

17

-

86

30

32

24

    

77

-

53

-

122

10

84

28

All RCTs

                    

Dropout (%)

40.38

9.35

10.43

16.23

56.81

11.53

18.24

27.04

52.46

22.98

9.12

15.44

42.83

11.39

17.30

9.81

62.87

9.92

27.43

25.53

Only RCTs with PANSS data

                    

Dropout (%)

36.22

6.79

10.77

15.16

56.81

11.53

18.24

27.04

43.62

17.45

8.72

11.19

42.83

11.39

17.30

9.81

62.87

9.92

27.43

25.53

Dash indicates missing data.

AE = adverse events; CW = consent withdrawal or other; LE = lack of efficacy; PANSS = Positive and Negative Syndrome Scale.

Table 4

Change in Positive and Negative Syndrome Scale (PANSS) scores in acute mania aripiprazole randomised controlled trials (RCTs)

Trial

3 weeks

12 weeks

N (efficacy sample)

 

PANSS-total

PANSS-positive

PANSS-negative

PANSS-cognitive

PANSS-hostility

PANSS-total

PANSS-positive

PANSS-negative

PANSS-cognitive

PANSS-hostility

 

Aripiprazole

 

CN138-009

-

-

-

-

-

     

125

CN138-074

-10.0 ± 18.2

-

-

-

-

     

136

CN138-135

-9.5 ± 17.4

-

-

-2.0 ± 4.6

-2.1 ± 4.6

-10.6 ± 19.4

-

-

-2.9 ± 5.7

-2.5 ± 4.6

154

CN138-162

-8.2 ± 12.9

-3.8 ± 5.1

-0.4 ± 2.6

-2.4 ± 3.9

-2.3 ± 3.9

-9.8 ± 14.2

-4.9 ± 5.2

-0.2 ± 2.6

-3.2 ± 5.2

-3.0 ± 3.9

152

CN138-007

-2 ± -a

-

-

-

-

     

267 -

CN138-008

-

-

-

-

-

-

-

-

-

-

171

Pooled mean

-6.5

-3.8

-0.4

-2.2

-2.2

-10.2

-4.9

-0.2

-3.0

-2.7

1,005

Pooled SD

16.3

5.1

2.6

4.3

4.3

16.9

5.2

2.6

5.5

4.3

 

Placebo

 

CN138-009

-

-

-

-

-

     

123

CN138-074

-5.3 ± 17.9

-

-

-

-

     

132

CN138-135

-4.9 ± 16.7

-

-

-0.9 ± 4.8

-1.0 ± 3.6

     

163

CN138-162

-4.7 ± 12.4

-2.4 ± 4.9

-0.1 ± 2.5

-1.5 ± 6.2

-1.2 ± 6.2

     

152

CN138-007

-2.3 ± -a

-

-

-

-

     

134 -

CN138-008

           

Pooled mean

-4.3

-2.4

-0.1

-1.2

-1.1

     

704

Pooled SD

15.8

4.9

2.5

5.5

5.0

      

Comparator

 

CN138-009

           

CN138-074

           

CN138-135

-7 ± 17.7

-

-

-1.6 ± 4.7

-1.6 ± 3.5

-7.4 ± 18.8

-

-

-2.0 ± 4.7

-1.8 ± 4.7

155

CN138-162

-8.8 ± 12.8

-4.2 ± 5.1

-0.3 ± 2.6

-2.5 ± 3.9

-2.6 ± 3.9

-11.7 ± 14.1

-5.4 ± 5.1

-0.3 ± 2.6

-3.9 ± 5.1

-3.5 ± 3.9

161

CN138-007

           

CN138-008

-

-

-

-

-

-

-

-

-

-

158

Pooled mean

-7.9

-4.2

-0.3

-2.0

-2.1

-9.6

-5.4

-0.3

-3

-2.7

474

Pooled SD

15.4

5.1

2.6

4.3

3.7

16.6

5.1

2.6

4.9

4.3

 

Dash indicates missing data.

aNot included in the calculation of the pooled measures because of a different study design (fixed dosage).

Table 5

Effect sizes for Positive and Negative Syndrome Scale (PANSS) total and subscales

 

PANSS total

PANSS-positive

PANSS-negative

PANSS-cognitive

PANSS-hostility

 

d

95% CI

d

95% CI

d

95% CI

d

95% CI

d

95% CI

Aripiprazole vs placebo

CN138-009

-

 

-

 

-

 

-

 

-

 

CN138-074

0.26

0.02 to 0.50

-

 

-

 

-

 

-

 

CN138-135

0.27

0.05 to 0.49

-

 

-

 

0.23

0.01- to 0.45

0.27

0.05 to 0.49

CN138-162

0.28

0.05 to 0.50

0.28

0.05 to 0.51

0.12

-0.11 to 0.34

0.17

-0.05 to 0.40

0.21

-0.01 to 0.44

CN138-007

-0.02

-0.23 to 0.19

-

 

-

 

-

 

-

 

CN138-008

-

 

-

 

-

 

-

 

-

 

Pooled mean

0.14

0.03 to 0.25

0.28

0.05 to 0.51

0.12

-0.11 to 0.34

0.20

0.04 to 0.36

0.24

0.08 to 0.39

Hunter-Schmidt d

0.18

0.176 to 0.184

-

 

-

 

0.20

-

0.24

-

Comparator vs placebo

CN138-135

0.12

-0.10 to 0.34

-

 

-

 

0.15

-0.07 to 0.37

0.17

-0.05 to 0.39

CN138-162

0.33

0.10 to 0.55

0.36

0.14 to 0.58

0.08

-0.14 to 0.30

0.19

-0.03 to 0.42

0.27

0.05 to 0.49

Pooled mean

0.23

0.10 to 0.36

0.36

0.14 to 0.58

0.08

-0.14 to 0.30

0.16

0.01 to 0.32

0.23

0.07 to 0.38

Dash indicates missing data.

Table 6

Side effects profile of aripiprazole in comparison to placebo (difference percentage).

Trial

Target

Overall side effects

Anxiety

Agitation

Acathisia

Constipation

Headache

Hyperprolactinaemia

Insomnia

Nausea

Sedation

CN138-009

Mania

 

8

1

9

7

5

-6

6

13

15

CN138-074

Mania

6

2

0.4

13.1

6.5

0.2

-7

 

5.5

9.4

CN138-135

Mania

   

8

4.3

0.8

  

9.3

6.8

CN138-162

Mania

0.1

11.4

 

6.8

 

1.8

 

2.1

 

5.4

CN138008

Mania

   

11.4

 

10.9

 

13.7

  

CN138-096

Depression

11

2.9

4.7

22.7

-1.5

-1.1

 

11.5

9.8

1.3

CN138-146

Depression

6

6.5

9.3

18.6

1.6

-2.3

 

7.7

6.6

1.1

CN138-010

Maintenance

6

-14.5

-10.8

6.6

 

7.8

 

-19.3

4.3

-7.2

CN138-134

Mania

8.3

  

13.2

    

5.2

 

Negative results suggest the effect in question was more frequent in the placebo group.

https://static-content.springer.com/image/art%3A10.1186%2F1744-859X-8-27/MediaObjects/12991_2009_Article_1411_Fig1_HTML.jpg
Figure 1

Forest plot of aripiprazole effect size against psychotic symptoms in acute mania (PANSS-total data).

After including only the RCTs reporting PANSS data (CN138009 and CN138007 were excluded), in total 1,640 patients were randomised and the total efficacy sample included 1,534 patients (613 in the aripiprazole group, 447 the placebo group and 474 in active control groups) while the safety sample included 1,574 (631 in the aripiprazole group, 450 in the placebo group and 493 in active control groups) (Table 1). The pooled dropout rate for the RCTs which reported PANSS data was 36.22% for aripiprazole, 43.62% for placebo and 42.83% for comparator at week 3, climbing to 56.81% and 62.87% at week 12 for aripiprazole and comparator, respectively. The dropout rates are shown in detail in Table 3.

The pooled d value for total PANSS score for all placebo-controlled studies with a fixed model was equal to 0.191 (95% CI 0.08 to 0.304), with a Q value equal to 5.024 (degrees of freedom (df) = 3; P = 0.170), which does not reject the homogeneity hypothesis. The I2 is equal to 40.283, which means that less than half of observed variability in the effect sizes across studies is due to true heterogeneity. However a random model gives similar results (d = 0.194; 95% CI 0.05 to 0.34). The Hunter-Schmidt method reports d = 0.18 (95% CI 0.176 to 0.184) after correcting for sampling and measurement error (Table 5).

Acute bipolar depression

There were two 8-week placebo controlled RCTs (CN138-096/NCT00080314 and CN138-146/NCT00094432) concerning the use of aripiprazole in acute bipolar depression, and were both negative at study endpoint [35]. These included non-psychotic bipolar depressives and thus do not report data on psychotic symptoms.

Maintenance treatment

There was one placebo-controlled RCT (CN138-010/NCT00036348) that studied aripiprazole in the maintenance phase [36]. Patients were stabilised with 15 to 30 mg of aripiprazole for 6 to 18 weeks and then randomised to a 1:1 ratio to aripiprazole or placebo for an additional 26 weeks. The baseline mean YMRS score was 2.5 ± 2.8 for the aripiprazole group and 2.1 ± 2.3 for the placebo group. The Montgomery-Åsberg Depression Rating Scale (MADRS) baseline scores were 3.9 ± 3.5 and 4.5 ± 4.2, respectively. Only anticholinergics and lorazepam were allowed as concomitant medication. During the 26 weeks 71.1% of patients under placebo and 71.4% of patients under aripiprazole received at least one concomitant medication. The primary efficacy outcome was time to relapse for a mood episode. From a total of 633 patients initially screened and 206 of them who completed the stabilisation phase, 161 were randomised (83 to placebo and 78 to aripiprazole). A total of 39 patients (50%) under aripiprazole and 28 (34%) under placebo completed the 26 weeks of the trial. The mean aripiprazole daily dosage at the end of 26 weeks was 24.3 mg. The time to relapse was significantly longer for aripiprazole (P = 0.02) and the hazard ratio (HR) was 0.52 (95% CI 0.30 to 0.91).

For the PANSS total score, a numerical trend favoured aripiprazole over placebo at any time point. At week 26, the changes (mean ± SD) in PANSS total scores were 5.2 ± 14.57 for aripiprazole and 9.1 ± 13.24 for placebo (P = 0.077), for the PANSS cognitive subscale score were for aripiprazole, 0.8 ± 4.55; placebo, 2.5 ± 4.41; P = 0.014) and for the PANSS hostility subscale score for aripiprazole, 0.8 ± 2.73; placebo, 1.8 ± 2.65; P = 0.032). All except the total PANSS score showed a significant superiority of aripiprazole over placebo, with d = 0.28, 0.38 and 0.71, respectively.

The adverse events reported by aripiprazole-treated patients at an incidence ≥ 5% and twice the incidence of placebo during the maintenance phase were tremor (9.1%), acathisia (6.5%), vaginitis (6.4%), and pain extremity (5.2%). One aripiprazole-treated patient and one placebo-treated patient attempted suicide in the stabilisation and maintenance phases, respectively. There were no significant differences concerning the QTc, while aripiprazole-treated patients showed a significant drop in prolactin levels. Concerning weight gain, 13% of aripiprazole-treated patients put > 7% of weight in comparison to none in the placebo group.

This same trial (CN138-010/NCT00036348) was expanded and included also a 74-week placebo controlled extension phase [37], which included 66 of the 67 patients who completed the 26-week period. Unfortunately only 12 of them (5 in the placebo group and 7 in the aripiprazole group) completed the 74-week treatment period. The reasons for this high discontinuation rate varied and included lack of efficacy, side effects (very low percentage) and most importantly the very design and structure of the study (the study was closed by the sponsor when the prespecified number of relapses had been attained). Because of this and because detailed descriptive data are not reported, arriving at conclusions is very difficult. The mean dosage of aripiprazole at the end of the 74-week period was 23.6 mg daily. It is reported that 29 out of the 66 patients relapsed (16 out of the 39 in the aripiprazole group (41%), and 13 out of the 27 in the placebo group (48.1%)). The only difference concerned manic relapses (nine in the placebo group and six in the aripiprazole group). Again the YMRS score significantly differed between groups. The adverse events had a similar rate to the 26-week period.

In both the above reports the median survival time for the aripiprazole group was not evaluable, while the median survival time for placebo was 118 to 203 days depending on the clinical subpopulation. At week 100, the changes (mean ± SD) in PANSS total scores were 7.9 ± 10.61 for aripiprazole and 11.8 ± 8.31 for placebo (P = 0.10), for the PANSS cognitive subscale score were for aripiprazole, 1.5 ± 3.12; placebo, 3.3 ± 2.59 (P = 0.01) and for the PANSS hostility subscale score for aripiprazole, 1.2 ± 2.49; placebo, 2.3 ± 2.07 (P = 0.03). Again all except the total PANSS score showed a significant superiority of aripiprazole over placebo, with d = 0.42, 0.63 and 0.48, respectively [38].

The expansion of the 135-008 trial [34] to a further 14 weeks failed to provide any results because of a high dropout rate, while the extension of the CN138-135/NCT00095511 trial [27] for an additional 40 weeks (52 weeks in total) comparing aripiprazole to lithium without a placebo arm suggested aripiprazole equal to lithium in the maintenance against manic episodes. No PANSS data are reported concerning this extension phase.

Discussion

The meta-analysis of the four trials that investigated the efficacy of aripiprazole on psychotic symptoms (assessed by the PANSS) during acute manic/mixed episodes suggests that the effect size versus placebo was equal to 0.14, but a more reliable and accurate estimation is 0.18 for the total PANSS score. The effect was higher for the PANSS positive subscale (0.28), PANSS hostility subscale (0.24) and PANSS cognitive subscale (0.20), and lower for the PANSS negative (0.12). The majority of these trials included patients with moderate to severe manic episodes, some of whom also had psychotic symptoms. No data on the depressive phase of bipolar illness exist, while there are some data in favour of aripiprazole concerning the maintenance phase, where at week 26 all except the total PANSS score showed a significant superiority of aripiprazole over placebo (d = 0.28 for positive, d = 0.38 for the cognitive and d = 0.71 for the hostility subscales) and at week 100 the results were similar (d = 0.42, 0.63 and 0.48, respectively). It is important to note that the efficacy for both haloperidol and lithium is similar to aripiprazole in the psychotic symptoms of BD. This could seem odd concerning lithium, which is not considered to possess antipsychotic efficacy (although it is recommended as augmentation strategy in refractory patients with schizophrenia). However the literature suggests that in essence lithium might exert a state-dependent effect on second messenger systems that is antidopaminergic-like during manic episodes (when dopaminergic activity seems to be elevated). Thus this state-dependent antidopaminergic activity could be responsible for this antipsychotic action [39, 40].

In comparison to the baseline scores reported in schizophrenia RCTs with aripiprazole, the respective PANSS scores in bipolar RCTs are significantly lower and this is of course expected. The PANSS-positive scores in schizophrenia RCTs range are around 29, for PANSS-negative they are around 22 and for PANSS-hostility around 9.5, while difference from placebo is again larger with 2.63 points difference in PANSS-positive, 2.31 points for PANSS-negative and 1.96 for PANSS-hostility [41]. However in these studies no standard deviations are reported and it is not possible to derive, thus the real effect sizes can not be calculated [42]. The only comparison that can be made is in terms of the ratio change to baseline. This ratio is similar for PANSS-positive (around 10%), but much different concerning PANSS-negative (10% in schizophrenia vs 3% in BD) and PANSS-hostility (20% for schizophrenia vs 11% for BD).

These results should be interpreted in light of recent studies on common genetic findings in schizophrenia and mood disorders [4347].

There are several meta-analyses in the literature concerning the efficacy of various agents in the treatment of bipolar illness, but none analyse the effect on psychotic symptoms [2128]. These meta-analyses suggest that aripiprazole's antimanic effect is specific and not limited to control of agitation through sedation, but no data on psychotic symptoms are analysed. Additionally, there is a concern regarding aripiprazole and olanzapine maintenance data because the relevant studies included patients who were responders specifically to the drug under investigation during the acute phase.

A few issues concerning the data of the RCTs should be pointed out however, because they reveal the restrictions of RCTs, as well as the gaps in our current knowledge and understanding and treating of bipolar illness. The first point is that although acute mania is generally considered one of the 'easier to treat' psychiatric conditions, with only 5% of bipolar patients experiencing chronic mania (although such a diagnostic condition is not recognised by the Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR)) [48], in the acute mania RCTs around half of acutely manic patients were non-responders at week 12, suggesting that they were not only chronic but maybe also refractory. The question whether the dosage should be raised is open and pressing. Higher dosages for all agents might be necessary to be studied. During the maintenance phase, around three-quarters of patients will drop out of aripiprazole treatment within the first year in comparison to almost all the patients under placebo, and although the difference is significant, it suggests that even under effective treatment, a significant number patients tend to relapse although at a lower frequency of episodes. Finally, the fixed dosage RCT was negative, suggesting that aripiprazole should be prescribed at an individualised basis. Similar issues have been recently raised because of the still unpublished results of the one study of paliperidone in acute mania, which also used a fixed dose approach (the second one utilised a flexible dosage design) and reported that 6 and 9 mg were not effective versus placebo while 12 mg was.

Conclusively, the data analysed for the current study supports the usefulness of aripiprazole against the psychotic symptoms during the acute manic/mixed and maintenance phases of bipolar illness, however there are specific issues the clinician should have in mind, such as that the maintenance effect is proven only in patients with an index manic episode that responded to aripiprazole during the acute phase. Higher and ever-increasing placebo rates constitute a problem of quality for RCTs today and limit the generalisability of results [49]. A limitation of this review is that most of the trials were sponsored by the pharmaceutical industry and were conducted to gain regulatory approval for aripiprazole for the treatment of bipolar disorder. Therefore, the possibility of sponsor bias induced in favour of their product cannot be excluded, especially since failed trials were not published and the available data from them are limited.

Declarations

Acknowledgements

KNF had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Authors’ Affiliations

(1)
Third Department of Psychiatry, Aristotle University of Thessaloniki
(2)
Department of Pharmacology and Pharmacotherapy and Department of Psychiatry Kutvolgyi Klinikai Tömb, Semmelweis University
(3)
Bipolar Disorders Program, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM
(4)
Tippie College of Business, University of Iowa

References

  1. Fountoulakis KN, Grunze H, Panagiotidis P, Kaprinis G: Treatment of bipolar depression: an update. J Affect Disord. 2008, 109 (1-2): 21-34. 10.1016/j.jad.2007.10.016.View ArticlePubMedGoogle Scholar
  2. Fountoulakis KN, Magiria S, Siamouli M, Panagiotidis P, Nimatoudis I, Iacovides A, Kaprinis GS: A seven- year follow-up of an extremely refractory bipolar I patient. CNS spectrums. 2007, 12 (10): 733-734.PubMedGoogle Scholar
  3. Fountoulakis KN, Vieta E, Sanchez-Moreno J, Kaprinis SG, Goikolea JM, Kaprinis GS: Treatment guidelines for bipolar disorder: a critical review. J Affect Disord. 2005, 86 (1): 1-10. 10.1016/j.jad.2005.01.004.View ArticlePubMedGoogle Scholar
  4. Fountoulakis KN, Vieta E, Siamouli M, Valenti M, Magiria S, Oral T, Fresno D, Giannakopoulos P, Kaprinis GS: Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder. Ann Gen Psychiatry. 2007, 6: 27-10.1186/1744-859X-6-27.PubMed CentralView ArticlePubMedGoogle Scholar
  5. Fountoulakis KN: The contemporary face of bipolar illness: complex diagnostic and therapeutic challenges. CNS spectrums. 2008, 13 (9): 763-774.PubMedGoogle Scholar
  6. Fountoulakis KN, Akiskal HS: Focus on bipolar illness. CNS Spectr. 2008, 13 (9): 762-PubMedGoogle Scholar
  7. Toni C, Perugi G, Frare F, Tusini G, Fountoulakis KN, Akiskal KK, Akiskal HS: The clinical-familial correlates and naturalistic outcome of panic-disorder-agoraphobia with and without lifetime bipolar II comorbidity. Ann Gen Psychiatry. 2008, 7: 23-10.1186/1744-859X-7-23.PubMed CentralView ArticlePubMedGoogle Scholar
  8. Mitchell PB, Goodwin GM, Johnson GF, Hirschfeld RM: Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disord. 2008, 10 (1 Pt 2): 144-152. 10.1111/j.1399-5618.2007.00559.x.View ArticlePubMedGoogle Scholar
  9. Akiskal HS, Benazzi F: Continuous distribution of atypical depressive symptoms between major depressive and bipolar II disorders: dose-response relationship with bipolar family history. Psychopathology. 2008, 41 (1): 39-42. 10.1159/000109954.View ArticlePubMedGoogle Scholar
  10. Selva G, Salazar J, Balanza-Martinez V, Martinez-Aran A, Rubio C, Daban C, Sanchez-Moreno J, Vieta E, Tabares-Seisdedos R: Bipolar I patients with and without a history of psychotic symptoms: do they differ in their cognitive functioning?. J Psychiatr Res. 2007, 41 (3-4): 265-272. 10.1016/j.jpsychires.2006.03.007.View ArticlePubMedGoogle Scholar
  11. Martinez-Aran A, Torrent C, Tabares-Seisdedos R, Salamero M, Daban C, Balanza-Martinez V, Sanchez-Moreno J, Manuel Goikolea J, Benabarre A, Colom F: Neurocognitive impairment in bipolar patients with and without history of psychosis. J Clin Psychiatry. 2008, 69 (2): 233-239. 10.4088/JCP.v69n0209.View ArticlePubMedGoogle Scholar
  12. Fountoulakis KN, Nimatoudis I, Iacovides A, Kaprinis G: Report of three cases that received maintenance treatment with risperidone as a mood stabilizer. Ann Gen Hosp Psychiatry. 2004, 3 (1): 10-10.1186/1475-2832-3-10.PubMed CentralView ArticlePubMedGoogle Scholar
  13. Fountoulakis KN, Nimatoudis I, Iacovides A, Kaprinis G: Off-label indications for atypical antipsychotics: A systematic review. Ann Gen Hosp Psychiatry. 2004, 3 (1): 4-10.1186/1475-2832-3-4.PubMed CentralView ArticlePubMedGoogle Scholar
  14. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, Morita S: 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-qui nolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther. 1995, 274 (1): 329-336.PubMedGoogle Scholar
  15. Oshiro Y, Sato S, Kurahashi N, Tanaka T, Kikuchi T, Tottori K, Uwahodo Y, Nishi T: Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives. J Med Chem. 1998, 41 (5): 658-667. 10.1021/jm940608g.View ArticlePubMedGoogle Scholar
  16. McIntyre RS, Soczynska JK, Woldeyohannes HO, Miranda A, Konarski JZ: Aripiprazole: pharmacology and evidence in bipolar disorder. Expert Opin Pharmacother. 2007, 8 (7): 1001-1009. 10.1517/14656566.8.7.1001.View ArticlePubMedGoogle Scholar
  17. McIntyre RS, Woldeyohannes HO, Yasgur BS, Soczynska JK, Miranda A, Konarski JZ: Maintenance treatment in bipolar disorder: a focus on aripiprazole. Expert Rev Neurother. 2007, 7 (8): 919-925. 10.1586/14737175.7.8.919.View ArticlePubMedGoogle Scholar
  18. Aitchison K, Bienroth M, Cookson J, Gray R, Haddad P, Moore B, Ratna L, Sullivan G, Taylor D, Taylor M: A UK consensus on the administration of aripiprazole for the treatment of mania. J Psychopharmacol. 2008Google Scholar
  19. Sanford M, Scott LJ: Intramuscular aripiprazole: a review of its use in the management of agitation in schizophrenia and bipolar I disorder. CNS Drugs. 2008, 22 (4): 335-352. 10.2165/00023210-200822040-00005.View ArticlePubMedGoogle Scholar
  20. Currier GW, Citrome LL, Zimbroff DL, Oren D, Manos G, McQuade R, Pikalov AA, Crandall DT: Intramuscular aripiprazole in the control of agitation. J Psychiatr Pract. 2007, 13 (3): 159-169. 10.1097/01.pra.0000271657.09717.e2.View ArticlePubMedGoogle Scholar
  21. Suppes T, Eudicone J, McQuade R, Pikalov A, Carlson B: Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. J Affect Disord. 2008, 107 (1-3): 145-154. 10.1016/j.jad.2007.08.015.View ArticlePubMedGoogle Scholar
  22. Sachs GS, Gaulin BD, Gutierrez-Esteinou R, McQuade RD, Pikalov A, Pultz JA, Sanchez R, Marcus RN, Crandall DT: Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline. J Clin Psychiatry. 2007, 68 (9): 1377-1383. 10.4088/JCP.v68n0908.View ArticlePubMedGoogle Scholar
  23. Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D: Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord. 2007, 9 (6): 551-560. 10.1111/j.1399-5618.2007.00468.x.View ArticlePubMedGoogle Scholar
  24. Cipriani A, Rendell JM, Geddes JR: Haloperidol alone or in combination for acute mania. Cochrane Database Syst Rev. 2006, 3: CD004362-PubMedGoogle Scholar
  25. Perlis RH, Welge JA, Vornik LA, Hirschfeld RM, Keck PE: Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry. 2006, 67 (4): 509-516. 10.4088/JCP.v67n0401.View ArticlePubMedGoogle Scholar
  26. Storosum JG, Wohlfarth T, Schene A, Elferink A, van Zwieten BJ, Brink van den W: Magnitude of effect of lithium in short-term efficacy studies of moderate to severe manic episode. Bipolar Disord. 2007, 9 (8): 793-798. 10.1111/j.1399-5618.2007.00445.x.View ArticlePubMedGoogle Scholar
  27. Keck PE, Orsulak PJ, Cutler AJ, Sanchez R, Torbeyns A, Marcus RN, McQuade RD, Carson WH: Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord. 2009, 112 (1-3): 36-49. 10.1016/j.jad.2008.05.014.View ArticlePubMedGoogle Scholar
  28. Tohen M, Zhang F, Taylor CC, Burns P, Zarate C, Sanger T, Tollefson G: A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. J Affect Disord. 2001, 65 (1): 85-93. 10.1016/S0165-0327(00)00162-2.View ArticlePubMedGoogle Scholar
  29. Hunter J, Schmidt F: Methods of Meta-Analysis: Correcting error and bias in Research findings. 2004, Sage Publications Inc., 2Google Scholar
  30. Keck PE, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G: A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003, 160 (9): 1651-1658. 10.1176/appi.ajp.160.9.1651.View ArticlePubMedGoogle Scholar
  31. Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, Abou-Gharbia N, Impellizzeri C, Kaplita S, Rollin L: Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006, 20 (4): 536-546. 10.1177/0269881106059693.View ArticlePubMedGoogle Scholar
  32. Young AH, Oren DA, Lowy A, McQuade RD, Marcus RN, Carson WH, Spiller NH, Torbeyns AF, Sanchez R: Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psychiatry. 2009, 194 (1): 40-48. 10.1192/bjp.bp.108.049965.View ArticlePubMedGoogle Scholar
  33. Garcia-Amador M, Pacchiarotti I, Valenti M, Sanchez RF, Goikolea JM, Vieta E: Role of aripiprazole in treating mood disorders. Expert review of neurotherapeutics. 2006, 6 (12): 1777-1783. 10.1586/14737175.6.12.1777.View ArticlePubMedGoogle Scholar
  34. Vieta E, Bourin M, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, Abou-Gharbia N, Swanink R, Iwamoto T: Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry. 2005, 187: 235-242. 10.1192/bjp.187.3.235.View ArticlePubMedGoogle Scholar
  35. Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, Carson WH, Marcus RN, Owen R: Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. 2008, 28 (1): 13-20. 10.1097/jcp.0b013e3181618eb4.View ArticlePubMedGoogle Scholar
  36. Keck PE, Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM, Marcus RN, Sanchez R: A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. 2006, 67 (4): 626-637. 10.4088/JCP.v67n0414.View ArticlePubMedGoogle Scholar
  37. Keck PE, Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM, Carlson BX, Marcus RN, Sanchez R: Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry. 2007, 68 (10): 1480-1491. 10.4088/JCP.v68n1003.View ArticlePubMedGoogle Scholar
  38. Muzina DJ, Momah C, Eudicone JM, Pikalov A, McQuade RD, Marcus RN, Sanchez R, Carlson BX: Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study. Int J Clin Pract. 2008, 62 (5): 679-687. 10.1111/j.1742-1241.2008.01735.x.PubMed CentralView ArticlePubMedGoogle Scholar
  39. Lenox R, Frazer A: Mechanism of action of antidepressants and mood stabilizers. Neuropsychopharmacology: The fifth generation of Progress. Edited by: Davis K, Charney D, Coyle J, Nemeroff C. 2002, Philadelphia: Lippincott Williams and Wilkins, 1139-1163.Google Scholar
  40. Corbella B, Vieta E: Molecular targets of lithium action. Acta Neuropsychiatrica. 2003, 15: 1-25. 10.1046/j.1601-5215.2003.00049.x.View ArticleGoogle Scholar
  41. Janicak PG, Glick ID, Marder SR, Crandall DT, McQuade RD, Marcus RN, Eudicone JM, Assuncao-Talbott S: The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. J Clin Psychiatry. 2009, 70 (1): 25-35. 10.4088/JCP.08m04310.View ArticlePubMedGoogle Scholar
  42. El-Sayeh HG, Morganti C, Adams CE: Aripiprazole for schizophrenia. Systematic review. Br J Psychiatry. 2006, 189: 102-108. 10.1192/bjp.189.2.102.View ArticlePubMedGoogle Scholar
  43. Prata DP, Breen G, Osborne S, Munro J, St Clair D, Collier DA: An association study of the neuregulin 1 gene, bipolar affective disorder and psychosis. Psychiatr Genet. 2009, 19 (3): 113-116. 10.1097/YPG.0b013e32832a4f69.View ArticlePubMedGoogle Scholar
  44. O'Donovan MC, Craddock NJ, Owen MJ: Genetics of psychosis; insights from views across the genome. Hum Genet. 2009, 126 (1): 3-12. 10.1007/s00439-009-0703-0.View ArticlePubMedGoogle Scholar
  45. Maziade M, Chagnon YC, Roy MA, Bureau A, Fournier A, Merette C: Chromosome 13q13-q14 locus overlaps mood and psychotic disorders: the relevance for redefining phenotype. Eur J Hum Genet. 2009, 17 (8): 1034-1042. 10.1038/ejhg.2008.268.PubMed CentralView ArticlePubMedGoogle Scholar
  46. Green EK, Grozeva D, Jones I, Jones L, Kirov G, Caesar S, Gordon-Smith K, Fraser C, Forty L, Russell E: The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. Mol Psychiatry. 2009Google Scholar
  47. Craddock N, O'Donovan MC, Owen MJ: Psychosis genetics: modeling the relationship between schizophrenia, bipolar disorder, and mixed (or "schizoaffective") psychoses. Schizophr Bull. 2009, 35 (3): 482-490. 10.1093/schbul/sbp020.PubMed CentralView ArticlePubMedGoogle Scholar
  48. Akiskal H: Mood Disorders. Comprehensive Textbook of Psychiatry. Edited by: Sadock B, Sadock V. 2000, Philadelphia: Lippincott Williams & Wilkins, I: 1338-1377.Google Scholar
  49. Vieta E, Cruz N: Increasing rates of placebo response over time in mania studies. J Clin Psychiatry. 2008, 69 (4): 681-682. 10.4088/JCP.v69n0423g.View ArticlePubMedGoogle Scholar

Copyright

© Fountoulakis et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement